-
NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
06 May 2024 13:16 GMT
… ;HHLA2 axis, announced today that Chief Executive Officer Ivan Cheung has been … , Mr. Cheung joined NextPoint as CEO in January 2024 aiming to … . He previously served as Eisai’s U.S. CEO, where he guided …
-
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim
12 May 2024 16:18 GMT
… ," Cuong Do, president and chief executive officer at BioVie, said in … placebo. In comparison, lecanemab (Leqembi; Eisai) and aducanumab (Aduhelm; Biogen), the …
-
Biogen 'turning the corner' as Leqembi and Skyclarys launches advance, but much work remains to be done: CEO
24 Apr 2024 23:25 GMT
… Leqembi and Skyclarys—the CEO has admitted that there … extraordinarily difficult launch.”
The CEO pointed to infrastructure challenges … will become integrated with Eisai, Alaimo explained.
Aside … ,” she explained.
While CEO Viehbacher acknowledged that he …
-
Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment
24 Apr 2024 11:37 GMT
… end of the collaboration, Eisai will evaluate the data … on BAN2802,” said Gunilla Osswald, chief executive officer, BioArctic.
She continued: …
Since 2005, BioArctic and Eisai’s collaboration has led to … of early AD.
While Eisai is responsible for the …
-
BioArctic, Eisai ink research evaluation agreement regarding BAN2802
23 Apr 2024 07:39 GMT
… s disease.
BioArctic and Eisai have a long-standing … said Gunilla Osswald, CEO at BioArctic. “Eisai has been a valuable … long-term collaboration with Eisai regarding the development and … commercialization agreement for lecanemab. Eisai is responsible for the …
-
BioArctic, Eisai Ink Research Agreement for BAN2802 in AD
22 Apr 2024 14:39 GMT
… 22.24
BioArctic AB and Eisai Co., Ltd., have entered … end of the collaboration, Eisai will evaluate the data generated … ;s disease.
BioArctic and Eisai have a long-standing collaboration … said Gunilla Osswald, CEO at BioArctic. "Eisai has been a valuable …
-
BioArctic and Eisai sign research evaluation agreement
22 Apr 2024 12:14 GMT
… the end of the collaboration, Eisai will evaluate the data generated … disorders,” says Gunilla Osswald, CEO at BioArctic. “Eisai has been a valuable … this devastating disease.”
BioArctic and Eisai have a long-standing collaboration …
-
BioArctic partners with Eisai on Alzheimer’s treatment
22 Apr 2024 08:39 GMT
… has signed an agreement with Eisai for a research evaluation … ’s disease.
BioArctic and Eisai’s partnership dates back to … of Alzheimer’s disease.
BioArctic CEO Gunilla Osswald said: “I …
Earlier this year, BioArctic and Eisai obtained approval for the amyloid …
-
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
20 Apr 2024 12:39 GMT
… Gunilla Osswald, CEO at BioArctic. "Eisai has been a … long-term collaboration with Eisai regarding the development and … commercialization agreement for lecanemab. Eisai is responsible for the … /bioarctic-and-eisai-sign-research-evaluation-agreement …
-
Biogen CEO Viehbacher sees 2023 pay fall to $4M after massive welcome package
17 Apr 2024 00:25 GMT
… for joining Biogen as the CEO in late 2022, Chris Viehbacher … in November 2022, the new CEO at that time agreed not … confirmed broad Medicare coverage—of Eisai-partnered Leqembi, a follow-on …